Limitations, agreements, and source contact

Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients · Source last updated 2021-05-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details

PI needs to inform sponsor and asks for permission before he/she discusses or publishes trial results after the trial is completed.

pi Sponsor Employee

false

restriction Type

OTHER

restrictive Agreement

true

point Of Contact

email

cetsai@taigenbiotech.com

organization

TaiGen Biotechnology Co., Ltd.

phone

+886-2-8177-7072

phone Ext

1211

title

Chen-En Tsai, M.D., Ph.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice